Mamegano Reiterates Buy on Takeda as Q1 Beat and Pipeline Progress Support Unchanged Price ObjectiveTip Ranks·7 hours agoTAK-2.90%4502
Takeda Pharmaceutical Company: Revenue up 10.2% on FX tailwinds; core profit flat at CER; FY2026 outlook cautiousQuartr·12 hours agoTAK-2.90%4502
Takeda Pharmaceutical Company: Q1 FY2026 delivered robust core revenue growth, driven by new launches and disciplined investmentQuartr·13 hours agoTAK-2.90%4502
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track | TAK Stock NewsStockTitan·21 hours agoTAK-2.90%4502
Inside the M&A Shuffles: Takeda, ZTO, and Pentair's $1.4B Buyout SignalGlobal Report·1 day ago, 04:19 AMTAK-2.90%ZTO0.00%
Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.2, Implies 10% UpsideTradingView·2 days ago, 09:20 AMTAK-2.90%4502
Takeda says China approves ORZEYFUL orexin agonist for narcolepsy type 1PUBT·Jul 22 at 09:10 PMTAK-2.90%4502
‘Historic breakthrough’: China approves novel drug ahead of US, Japan and EuropeSCMP·Jul 21 at 11:04 PMTAK-2.90%4502
Weekly Recap: India approves QDENGA and LATITUDE PsO trial successTradingView·Jul 20 at 05:14 PMTAK-2.90%4502
Novartis and Takeda drugs gain rare blood cancer routine use on NHSPharmaceutical Technology·Jul 20 at 05:46 AM4502TAK-2.90%
